Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
- Sponsor
- Incyte Corporation
- Study ID
- NCT05561985
- Status
- Available
Conditions
- STAT1 Gain-of-Function Disease
Eligibility Criteria
- Sex
- All
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Itacitinib — DRUG
Study Details
Expanded access use of Itacitinib to treat a single patient with aplastic anemia.
Key Dates
- Status verified
- Jun 2026
Central Contacts
- Incyte Corporation Call Center (US)1.855.463.3463